{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:25:46Z","timestamp":1792661146666,"version":"4.5.0"},"reference-count":40,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"7","funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["EB024495"],"award-info":[{"award-number":["EB024495"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014561","name":"Juno Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014561","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2019,7,5]]},"abstract":"<jats:p>PET targeting a mutated PSMA enabled serial imaging of CAR T cell activity in a murine model of ALL.<\/jats:p>","DOI":"10.1126\/sciadv.aaw5096","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T19:15:33Z","timestamp":1562181333000},"source":"Crossref","is-referenced-by-count":134,"title":["Imaging CAR T cell therapy with PSMA-targeted positron emission tomography"],"prefix":"10.1126","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-662X","authenticated-orcid":true,"given":"Il","family":"Minn","sequence":"first","affiliation":[{"name":"Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Huss","sequence":"additional","affiliation":[{"name":"Juno Therapeutics, Seattle, WA 98109, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Hyun","family":"Ahn","sequence":"additional","affiliation":[{"name":"Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara M.","family":"Chinn","sequence":"additional","affiliation":[{"name":"Juno Therapeutics, Seattle, WA 98109, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Park","sequence":"additional","affiliation":[{"name":"Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-3337","authenticated-orcid":true,"given":"Jon","family":"Jones","sequence":"additional","affiliation":[{"name":"Juno Therapeutics, Seattle, WA 98109, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-6153","authenticated-orcid":true,"given":"Mary","family":"Brummet","sequence":"additional","affiliation":[{"name":"Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Sysa-Shah","sequence":"additional","affiliation":[{"name":"Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-6154","authenticated-orcid":true,"given":"Yong","family":"Du","sequence":"additional","affiliation":[{"name":"Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-3871","authenticated-orcid":true,"given":"Hyam I.","family":"Levitsky","sequence":"additional","affiliation":[{"name":"Juno Therapeutics, Seattle, WA 98109, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-3010","authenticated-orcid":true,"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[{"name":"Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.01.010"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.06.004"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-786129"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer J. N.","year":"2017","unstructured":"J. N. Kochenderfer, R. P. T. Somerville, T. Lu, J. C. Yang, R. M. Sherry, S. A. Feldman, L. McIntyre, A. Bot, J. Rossi, N. Lam, S. A. Rosenberg, Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25, 2245\u20132253 (2017).","journal-title":"Mol. Ther."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1042\/BST20150257","article-title":"Dynamic imaging for CAR-T-cell therapy","volume":"44","author":"Emami-Shahri N.","year":"2016","unstructured":"N. Emami-Shahri, S. Papa, Dynamic imaging for CAR-T-cell therapy. Biochem. Soc. Trans. 44, 386\u2013390 (2016).","journal-title":"Biochem. Soc. Trans."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17669-4"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/s41467-018-03524-1","article-title":"Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells","volume":"9","author":"Emami-Shahri N.","year":"2018","unstructured":"N. Emami-Shahri, J. Foster, R. Kashani, P. Gazinska, C. Cook, J. Sosabowski, J. Maher, S. Papa, Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. Nat. Commun. 9, 1081 (2018).","journal-title":"Nat. Commun."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag2196"},{"key":"e_1_3_2_17_2","first-page":"e90064","article-title":"Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors","volume":"1","author":"Vedyvas Y.","year":"2016","unstructured":"Y. Vedyvas, E. Shevlin, M. Zaman, I. M. Min, A. Amor-Coarasa, S. Park, S. Park, K.-W. Kwon, T. Smith, Y. Luo, D. Kim, Y. Kim, B. Law, R. Ting, J. Babich, M. M. Jin, Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight 1, e90064 (2016).","journal-title":"JCI Insight"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.trecan.2018.03.009","article-title":"Noninvasive PET Imaging of T cells","volume":"4","author":"Wei W.","year":"2018","unstructured":"W. Wei, D. Jiang, E. B. Ehlerding, Q. Luo, W. Cai, Noninvasive PET Imaging of T cells. Trends Cancer 4, 359\u2013373 (2018).","journal-title":"Trends Cancer"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"9389","DOI":"10.1158\/0008-5472.CAN-07-0944","article-title":"ABCG2\/BCRP expression modulates D-Luciferin\u2013based bioluminescence imaging","volume":"67","author":"Zhang Y.","year":"2007","unstructured":"Y. Zhang, J. P. Bressler, J. Neal, B. Lal, H.-E. Bhang, J. Laterra, M. G. Pomper, ABCG2\/BCRP expression modulates D-Luciferin\u2013based bioluminescence imaging. Cancer Res. 67, 9389\u20139397 (2007).","journal-title":"Cancer Res."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13550-017-0280-5","article-title":"Tracking dendritic cell migration into lymph nodes by using a novel PET probe 18F-tetrafluoroborate for sodium\/iodide symporter","volume":"7","author":"Lee S. B.","year":"2017","unstructured":"S. B. Lee, H. W. Lee, H. J. Lee, Y. H. Jeon, S.-W. Lee, B.-C. Ahn, S. Y. Jeong, Tracking dendritic cell migration into lymph nodes by using a novel PET probe 18F-tetrafluoroborate for sodium\/iodide symporter. EJNMMI Res. 7, 32 (2017).","journal-title":"EJNMMI Res."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11154-018-9470-3","article-title":"Somatostatin receptor expression in non-classical locations\u2014Clinical relevance?","volume":"19","author":"Bhanat E.","year":"2018","unstructured":"E. Bhanat, C. A. Koch, R. Parmar, V. Garia, V. Vijayakumar, Somatostatin receptor expression in non-classical locations\u2014Clinical relevance? Rev. Endocr. Metab. Disord. 19, 123\u2013132 (2018).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.134031"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00278-7"},{"key":"e_1_3_2_24_2","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver D. A.","year":"1997","unstructured":"D. A. Silver, I. Pellicer, W. R. Fair, W. D. Heston, C. Cordon-Cardo, Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81\u201385 (1997).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","author":"Szabo Z.","year":"2015","unstructured":"Z. Szabo, E. Mena, S. P. Rowe, D. Plyku, R. Nidal, M. A. Eisenberger, E. S. Antonarakis, H. Fan, R. F. Dannals, Y. Chen, R. C. Mease, M. Vranesic, A. Bhatnagar, G. Sgouros, S. Y. Cho, M. G. Pomper, Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol. Imaging Biol. 17, 565\u2013574 (2015).","journal-title":"Mol. Imaging Biol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-based [18F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer","volume":"18","author":"Rowe S. P.","year":"2016","unstructured":"S. P. Rowe, K. J. Macura, E. Mena, A. L. Blackford, R. Nadal, E. S. Antonarakis, M. Eisenberger, M. Carducci, H. Fan, R. F. Dannals, Y. Chen, R. C. Mease, Z. Szabo, M. G. Pomper, S. Y. Cho, PSMA-based [18F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol. Imaging Biol. 18, 411\u2013419 (2016).","journal-title":"Mol. Imaging Biol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.118.217588","article-title":"Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET\/CT Imaging","volume":"59","author":"Werner R. A.","year":"2018","unstructured":"R. A. Werner, R. A. Bundschuh, L. Budndschuh, M. S. Javadi, J. P. Leal, T. Higuchi, K. J. Pienta, A. K. Buck, M. G. Pomper, M. A. Gorin, C. Lapa, S. P. Rowe, Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET\/CT Imaging. J. Nucl. Med. 59, 1857\u20131864 (2018).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","article-title":"PSMA-RADS version 1.0: A step towards standardizing the interpretation and reporting of PSMA\u2013targeted PET imaging studies","volume":"73","author":"Rowe S. P.","year":"2018","unstructured":"S. P. Rowe, K. J. Pienta, M. G. Pomper, M. A. Gorin, PSMA-RADS version 1.0: A step towards standardizing the interpretation and reporting of PSMA\u2013targeted PET imaging studies. Eur. Urol. 73, 485\u2013487 (2018).","journal-title":"Eur. Urol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen\u2013targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe S. P.","year":"2018","unstructured":"S. P. Rowe, K. J. Pienta, M. G. Pomper, M. A. Gorin, Proposal for a structured reporting system for prostate-specific membrane antigen\u2013targeted PET imaging: PSMA-RADS version 1.0. J. Nucl. Med. 59, 479\u2013485 (2018).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/jlcr.3430","article-title":"An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL","volume":"59","author":"Ravert H. T.","year":"2016","unstructured":"H. T. Ravert, D. P. Holt, Y. Chen, R. C. Mease, H. Fan, M. G. Pomper, R. F. Dannals, An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL. J. Labelled Comp. Radiopharm. 59, 439\u2013450 (2016).","journal-title":"J. Labelled Comp. Radiopharm."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e02-11-0731"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","author":"Chen Y.","year":"2011","unstructured":"Y. Chen, M. Pullambhatla, Y. Byun, C. A. Foss, S. Nimmagadda, S. Senthamizhchelvan, G. Sgouros, R. C. Mease, M. G. Pomper, 2-(3-{1carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 17, 7645\u20137653 (2011).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer","volume":"17","author":"Dietlein M.","year":"2015","unstructured":"M. Dietlein, C. Kobe, G. Kuhnert, S. Stockter, T. Fischer, K. Schomacker, M. Schmidt, F. Dietlein, B. D. Zlatopolskiy, P. Krapf, R. Richarz, S. Neubauer, A. Drzezga, B. Neumaier, Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol. Imaging Biol. 17, 575\u2013584 (2015).","journal-title":"Mol. Imaging Biol."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-018-0382-8","article-title":"Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: A comparison with 18F-DCFPyl and 18F-PSMA-1007","volume":"8","author":"Robu S.","year":"2018","unstructured":"S. Robu, A. Schmidt, M. Eiber, M. Schottelius, T. G\u00fcnther, B. Hooshyar Yousefi, M. Schwaiger, H.-J. Wester, Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: A comparison with 18F-DCFPyl and 18F-PSMA-1007. EJNMMI Res. 8, 30 (2018).","journal-title":"EJNMMI Res."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj N.","year":"2018","unstructured":"N. Bouchkouj, Y. L. Kasamon, R. A. de Claro, B. George, X. Lin, S. Lee, G. M. Blumenthal, W. Bryan, A. E. McKee, R. Pazdur, FDA approval summary: Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin. Cancer Res. 25, 1702\u20131708 (2018).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02493"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2967\/jnumed.117.202945","article-title":"Impact of 68Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence","volume":"59","author":"Calais J.","year":"2018","unstructured":"J. Calais, W. P. Fendler, M. Eiber, J. Gartmann, F. I. Chu, N. G. Nickols, R. E. Reiter, M. B. Rettig, L. S. Marks, T. E. Ahlering, L. M. Huynh, R. Slavik, P. Gupta, A. Quon, M. S. Allen-Auerbach, J. Czernin, K. Herrmann, Impact of 68Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence. J. Nucl. Med. 59, 434\u2013441 (2018).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_40_2","article-title":"Results of a prospective phase 2 pilot trial of 177Lu\u2013PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","author":"Emmett L.","year":"2018","unstructured":"L. Emmett, M. Crumbaker, B. Ho, K. Willowson, P. Eu, L. Ratnayake, R. Epstein, A. Blanksby, L. Horvath, A. Guminski, K. Mahon, C. Gedye, C. Yin, P. Stricker, A. M. Joshua, Results of a prospective phase 2 pilot trial of 177Lu\u2013PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin. Genitourin. Cancer (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies","volume":"32","author":"Gust J.","year":"2018","unstructured":"J. Gust, A. Taraseviciute, C. J. Turtle, Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 32, 1091\u20131101 (2018).","journal-title":"CNS Drugs"}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.aaw5096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:48:49Z","timestamp":1704804529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.aaw5096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,5]]}},"alternative-id":["10.1126\/sciadv.aaw5096"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.aaw5096","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"article-number":"eaaw5096"}}